Developmental funds will be used to provide startup funds for the recruitment of outstanding scientists to Purdue and to support the development of a new drug discovery shared resource. Molecular Discovery and Evaluation (MDE). Support of faculty recruitment focuses on adding faculty whose research interests represent strategic additions to the Center. These funds are intended to assist in providing newly recruited faculty members with the resources to establish their research programs and attract independent research support. The Center is involved in joint recruitments with key Departments on campus to enhance cancerfocused research at Purdue University. Currently, four such recruitments are in progress. The Center strategic plan includes enhancing research and shared resource strengths of the Center through faculty recruitment. Thus, ample the recruitment of additional new faculty will be vigorously pursued over the next five years. Support for the development of the MDE share resource will provide needed expansion of drug development services. The MDE will expand and automate previous drug discovery services provided by the Purdue University Center for Cancer Research. The primary mission of the MDE developmental shared resource is to enhance the capacity of the Purdue University Center for Cancer Research to accelerate therapeutic development including targeted agents. Funds are sought to partially support the development of the shared resource.
; Development funds are used by leadership to recruit new and talented investigators to the Center. Their recruitment brings in new expertise that enhances discovery and broadens collaborative efforts. New discoveries lead to new approaches for reducing the pain and suffering caused by cancer.
|Wyatt-Johnson, Season K; Herr, Seth A; Brewster, Amy L (2017) Status Epilepticus Triggers Time-Dependent Alterations in Microglia Abundance and Morphological Phenotypes in the Hippocampus. Front Neurol 8:700|
|Orellana, Esteban A; Tenneti, Srinivasarao; Rangasamy, Loganathan et al. (2017) FolamiRs: Ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer. Sci Transl Med 9:|
|Wu, M-J; Kim, M R; Chen, Y-S et al. (2017) Retinoic acid directs breast cancer cell state changes through regulation of TET2-PKC? pathway. Oncogene 36:3193-3206|
|Han, Ning; Pang, Liang; Xu, Jun et al. (2017) Development of Surface-Variable Polymeric Nanoparticles for Drug Delivery to Tumors. Mol Pharm 14:1538-1547|
|Li, Jie; Wang, Ruixin; Kong, Yifan et al. (2017) Targeting Plk1 to Enhance Efficacy of Olaparib in Castration-Resistant Prostate Cancer. Mol Cancer Ther 16:469-479|
|Jang, Yumi; Rao, Xiayu; Jiang, Qing (2017) Gamma-tocotrienol profoundly alters sphingolipids in cancer cells by inhibition of dihydroceramide desaturase and possibly activation of sphingolipid hydrolysis during prolonged treatment. J Nutr Biochem 46:49-56|
|Wang, Siwen; Xing, Zheng; Pascuzzi, Pete E et al. (2017) Metabolic Adaptation to Nutrients Involves Coregulation of Gene Expression by the RNA Helicase Dbp2 and the Cyc8 Corepressor in Saccharomyces cerevisiae. G3 (Bethesda) 7:2235-2247|
|Yue, Feng; Bi, Pengpeng; Wang, Chao et al. (2017) Pten is necessary for the quiescence and maintenance of adult muscle stem cells. Nat Commun 8:14328|
|Li, Guo; Low, Philip S (2017) Synthesis and evaluation of a ligand targeting the ? and ? opioid receptors for drug delivery to lung cancer. Bioorg Med Chem Lett 27:2074-2078|
|Chen, I-Hsuan; Xue, Liang; Hsu, Chuan-Chih et al. (2017) Phosphoproteins in extracellular vesicles as candidate markers for breast cancer. Proc Natl Acad Sci U S A 114:3175-3180|
Showing the most recent 10 out of 370 publications